Diabetes drug may fight inflammation after stent procedure

NCT ID NCT07292909

Recruiting now Disease control Sponsor: Hotel Dieu de France Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether empagliflozin, a diabetes drug, can reduce inflammation after a heart stent procedure. 100 patients with stable coronary artery disease will take either empagliflozin or a placebo for three days before their scheduled stent placement. Researchers will measure C-reactive protein (CRP) levels before and after the procedure to see if the drug lowers the inflammatory response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin
What this could lead to: If it works, this could show that empagliflozin reduces inflammation after stent placement, potentially improving recovery and outcomes for heart patients.
What could go wrong: This is a small, early-phase trial focused on a biomarker (CRP), not clinical outcomes. The anti-inflammatory effect may be modest or not translate to real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAD - CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAD - CORONARY ARTERY DISEASE INFLAMATION PCI SGLT 2 INHIBITORS

Contacts and locations

Locations

Hotel Dieu de France
RECRUITING

Beirut, Beirut, 00000, Lebanon

More trials for these conditions

Other studies related to the condition(s) this trial covers.